抗DR4抗体 | Anti-DR4 antibody

• 特長
• 価格
• DATA IMAGES
• 製品情報
• APPLICATION
• PROPERTIES
• TARGET
• REFERENCEE(抜粋)

特長

• 高品質の抗体です。
• 幅広い研究分野に関連する抗体を取り揃えています。
• 使用されたアプリケーションや動物種などの情報が充実しています。
• 多数の論文で使用実績がある信頼性の高い抗体です。

目次に戻る

価格

目次に戻る

DATA IMAGES

	ICC/IF analysis of Jurkat cells using GTX28414 DR4 antibody. Working concentration : 10 μg/ml
	WB analysis of (A) HepG2 and (B) Jurkat cell lysate using GTX28414 DR4 antibody. Working concentration : 1 μg/ml
	IHC-P analysis of human spleen tissue using GTX28414 DR4 antibody. Working concentration : 5 μg/ml
	IHC-P analysis of human spleen tissue using GTX28414 DR4 antibody. Working concentration : 20 μg/ml

目次に戻る

製品情報

Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Application	WB, ICC/IF, IHC-P, ELISA
Reactivity	Human

目次に戻る

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Application	Dilution
WB	1 μg/mL
ICC/IF	10 μg/mL
IHC-P	5 μg/mL
ELISA	Assay dependent

Not tested in other applications.

Calculated MW	50 kDa. ( Note )
Positive Control	Jurkat Cell Lysate(GTX27899) , HepG2 Cell Lysate(GTX27900) , Human Spleen Tissue Slide
Specificity/Sensitivity	Does not cross react with DR5.

目次に戻る

PROPERTIES

Form	Liquid
Buffer	PBS with 0.02% sodium azide.
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration	1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species	Human
Immunogen	Synthetic peptide, corresponding to amino acids 427-445 of Human DR4.
Purification	Purified by antigen-affinity chromatography
Conjugation	Unconjugated
Note	For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

目次に戻る

TARGET

Synonyms	TNF receptor superfamily member 10a , APO2 , CD261 , DR4 , TRAILR-1 , TRAILR1
Cellular Localization	Membrane; Single-pass type I membrane protein
Background	Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1and Fas. A novel cell death receptor was recently identified and designated DR4 (for death receptor4)(1). The ligand for this novel death receptor has been identified and termed TRAIL (2,3), which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1)(4). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4mediates apoptosis and NF-kB activation in many tissues and cells.
Database	・ Gene ID: 8797 TNFRSF10A ・ UniProt: O00220 TNFRSF10A

目次に戻る

REFERENCEE(抜粋)

Application Reference	Application/Reactivity
Dine JL et al. Breast Cancer Res Treat 2016; 155 (2) : 235-51 The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.	Application : WB Reactivity : Human
Ou YC et al. Life Sci 2014; 100 (2) : 110-7 Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis.	Application : WB Reactivity : Human
Garimella SV et al. Mol Cancer Res 2012; 10 (1) : 75-85 WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.	Application : WB Reactivity : Human

目次に戻る